1. 268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101). (10th December 2020) Authors: Berton-Rigaud, Dominique; Vergote, Ignace; Pautier, Patricia; Kryzhanivska, Anna; Angelergues, Antoine; Kornacki, Deanna; Dudzisz-Sledz, Monika; Tian, Chuan; Bourayou, Nawel; Selle, Frederic Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A164 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101). (9th November 2020) Authors: Berton-Rigaud, Dominique; Vergote, Ignace; Pautier, Patricia; Kryzhanivska, Anna; Angelergues, Antoine; Kornacki, Deanna; Dudzisz-Sledz, Monika; Tian, Chuan; Bourayou, Nawel; Selle, Frederic Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A294 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO). (9th November 2020) Authors: Slomovitz, Brian; Monk, Bradley; Moxley, Katherine; Ghali, Nadeem; Sokol, Justyna Fronczek; Tian, Chuan; Bourayou, Nawel; Sehouli, Jalid Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A374 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗